France· FR:66204797
XOSPATA 40 mg, comprimé pelliculé
A medicinal product containing fumarate de giltéritinib, registered in France by ASTELLAS PHARMA EUROPE (PAYS-BAS), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- FUMARATE DE GILTÉRITINIB
- Manufacturer
- ASTELLAS PHARMA EUROPE (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009301907844 plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 21 comprimé(s)EUR 15.96
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fumarate de giltéritinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumXospata 40 mgAstellas Pharma Europe
- SwitzerlandXospata 40 mg, FilmtablettenAstellas Pharma AG
- CzechiaXOSPATAAstellas Pharma Europe B.V., Leiden
- SpainXOSPATA 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstellas Pharma Europe B.V.
- FinlandXospataAstellas Pharma Europe B.V.
- IrelandXospata 40 mg film-coated tabletsAstellas Pharma Europe B.V.
- NetherlandsXospata 40 mg, filmomhulde tablettenAstellas Pharma Europe B.V.
- NorwayXospataAstellas Pharma Europe B.V. - Leiden
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xospata
- Liechtenstein · Xospata
- Norway · Xospata
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3f889fd0-9e9e-479e-983e-10db8578550a GET /v1/drugs/3f889fd0-9e9e-479e-983e-10db8578550a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66204797",
"date_amm": "2019-10-24",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/19/1399",
"substance": "FUMARATE DE GILTÉRITINIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about fumarate de giltéritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.